Theriva Biologics Announces Presentation At ESMO Congress 2023 Featuring Survival Outcomes In Phase 1 Study Evaluating VCN-01 In Combination With Durvalumab In Patients With Recurrent/Metastatic Squamous Cell Carcinoma Of The Head And Neck
Portfolio Pulse from Benzinga Newsdesk
Theriva Biologics (NYSE:TOVX) has announced the presentation of Phase 1 data from a study evaluating VCN-01 in combination with durvalumab for patients with recurrent/metastatic squamous cell carcinoma of the head and neck. The study, conducted in collaboration with the Institut Catala d'Oncologia, showed enhanced patient survival, correlating with VCN-01 induced upregulation of PD(L)-1. The data will be presented at the European Society for Medical Oncology Congress in October 2023.
October 16, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Theriva Biologics' announcement of positive Phase 1 data for VCN-01 in combination with durvalumab could potentially boost investor confidence and positively impact the company's stock price in the short term.
The announcement of positive Phase 1 data for a drug under development is typically seen as a positive signal by investors, as it indicates progress in the drug's development and increases the likelihood of eventual regulatory approval and commercialization. This could lead to increased investor confidence in Theriva Biologics and a potential increase in the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100